CJC-1295 (no DAC)
Also known as Mod GRF 1-29, CJC-1295 without DAC
Short-acting growth hormone releasing hormone analogue.
- Category
- muscle
- Route
- subq
- Documented dose
- 100–300 mcg
- Typical frequency
- Once to three times daily
- Cycle
- 12 weeks on, 4 off
- Half-life
- ~30 minutes
- Common vial sizes
- 2 mg, 5 mg
- Regulatory status
- Not approved for human use in most jurisdictions.
What it does
Also called Mod GRF 1-29. It nudges the pituitary gland to release your own growth hormone in a natural burst, rather than adding synthetic hormone from outside. What people look into it for: • Better deep sleep and feeling more rested • Faster recovery between training sessions • Gradual improvements in lean muscle and body composition • Skin, hair and connective-tissue quality Because it clears quickly, it is usually dosed before bed and often paired with a ghrelin-type peptide such as ipamorelin for a stronger pulse.
Mechanism
GHRH analogue binding pituitary GHRH receptors to stimulate endogenous GH secretion.
Storage — lyophilised
Refrigerate 2-8C, protect from light.
Storage — reconstituted
Refrigerate 2-8C, use within ~28 days.
Reconstitution notes
Add 2 ml bacteriostatic water to a 2 mg vial for 10 mcg per unit.
Commonly stacked with
- Ipamorelin
Commonly reported side effects
- Injection-site redness
- Water retention
- Head rush
- Tingling hands
Contraindications noted
- Active malignancy
- Pregnancy or breastfeeding
- Uncontrolled diabetes
Research notes
Best characterised when dosed on an empty stomach; frequently paired with Ipamorelin in the literature.
Track this properly
Work out syringe units with the free calculator, or set up a full schedule in about a minute.
Reference information only, not medical advice. See our medical disclaimer.